MB

Meekyung Bae

Chief Of Marketing Strategy Office at JW Pharmaceutical Corporation

Meekyung Bae is an accomplished marketing professional with extensive experience in the pharmaceutical industry. Currently serving as the Chief of Marketing Strategy Office at JW Pharmaceutical Corporation since December 2023, Meekyung previously held the position of Director, Medical Marketing BU at KEYMEDI from April 2021 to February 2023. Prior roles include Director of the Virology Business Unit at Bristol-Myers Squibb and various leadership positions at Novartis Korea, including Head of Neuroscience and Marketing Manager roles. Meekyung started the career in marketing at Novartis Pharma AG Basel as a Marketing Science Manager in 2007. Educational credentials include an MBA in Marketing from Temple University and a Master’s degree in Pharmacology, along with a Bachelor of Science in Industrial Pharmacy, both from Ewha Womans University.

Location

Seoul, Republic of Korea

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


JW Pharmaceutical Corporation

JW Pharmaceutical Corp. (formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach. ------- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, iii) excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012